BACKGROUND: Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons learned. With the World Health Organization (WHO) guidelines used as a frame of reference, we assessed the feasibility of implementing such programs in Africa. Moreover, clinical and laboratory outcomes were compiled to determine the effectiveness of HAART programs. METHODS: We searched academic databases and recent conference abstracts for studies, and we included all studies that documented patients receiving HAART in Africa. In particular, we examined studies for such program features as type of regimen and frequency of monitoring, in addition to evaluations of patient outcomes. RESULTS: Twenty-eight articles and abstracts involving studies from 14 African countries were reviewed. Overall, 6052 patients (96.4%) were receiving HAART, mainly consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor. All studies reported an increase in mean and median CD4 cell counts, and a median of 73% of patients achieved undetectable viral loads by the end of the study period. Monitoring of CD4 cell count and viral load at 6-month intervals was completed by all studies. The median weight gained was 5.0 kg, and the median mortality rate was 7.4% (range, 0%-27%). Six studies reported that 68%-99% of patients took >95% of medications. Five studies measured drug resistance; most cases of resistance involved NRTIs. CONCLUSIONS: Many studies reported positive health outcomes, including high levels of treatment adherence that were comparable to those of industrialized countries. Regimens and monitoring means based on WHO guidelines were implemented--and at times, exceeded--in all studies reviewed. We found compelling evidence that HAART can be feasibly administered in resource-limited settings.
BACKGROUND: Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons learned. With the World Health Organization (WHO) guidelines used as a frame of reference, we assessed the feasibility of implementing such programs in Africa. Moreover, clinical and laboratory outcomes were compiled to determine the effectiveness of HAART programs. METHODS: We searched academic databases and recent conference abstracts for studies, and we included all studies that documented patients receiving HAART in Africa. In particular, we examined studies for such program features as type of regimen and frequency of monitoring, in addition to evaluations of patient outcomes. RESULTS: Twenty-eight articles and abstracts involving studies from 14 African countries were reviewed. Overall, 6052 patients (96.4%) were receiving HAART, mainly consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor. All studies reported an increase in mean and median CD4 cell counts, and a median of 73% of patients achieved undetectable viral loads by the end of the study period. Monitoring of CD4 cell count and viral load at 6-month intervals was completed by all studies. The median weight gained was 5.0 kg, and the median mortality rate was 7.4% (range, 0%-27%). Six studies reported that 68%-99% of patients took >95% of medications. Five studies measured drug resistance; most cases of resistance involved NRTIs. CONCLUSIONS: Many studies reported positive health outcomes, including high levels of treatment adherence that were comparable to those of industrialized countries. Regimens and monitoring means based on WHO guidelines were implemented--and at times, exceeded--in all studies reviewed. We found compelling evidence that HAART can be feasibly administered in resource-limited settings.
Authors: Joshua M Wong; Leonard Cosmas; Dhillon Nyachieo; John M Williamson; Beatrice Olack; George Okoth; Henry Njuguna; Daniel R Feikin; Heather Burke; Joel M Montgomery; Robert F Breiman Journal: J Infect Dis Date: 2015-02-25 Impact factor: 5.226
Authors: F Touzard Romo; L M Smeaton; T B Campbell; C Riviere; R Mngqibisa; M Nyirenda; K Supparatpinyo; N Kumarasamy; J G Hakim; T P Flanigan Journal: HIV Clin Trials Date: 2014 Nov-Dec
Authors: Hermann Bussmann; C William Wester; Ann Thomas; Vladimir Novitsky; Reginald Okezie; Tanaka Muzenda; Tendani Gaolathe; Ndwapi Ndwapi; Norah Mawoko; Erik Widenfelt; Sikhulile Moyo; Rosemary Musonda; Madisa Mine; Joseph Makhema; Howard Moffat; Max Essex; Victor Degruttola; Richard G Marlink Journal: J Acquir Immune Defic Syndr Date: 2009-05-01 Impact factor: 3.731
Authors: Mhairi Maskew; Alana T Brennan; Daniel Westreich; Lynne McNamara; A Patrick MacPhail; Matthew P Fox Journal: J Womens Health (Larchmt) Date: 2013-01-25 Impact factor: 2.681
Authors: Rochelle P Walensky; Robin Wood; Milton C Weinstein; Neil A Martinson; Elena Losina; Mariam O Fofana; Sue J Goldie; Nomita Divi; Yazdan Yazdanpanah; Bingxia Wang; A David Paltiel; Kenneth A Freedberg Journal: J Infect Dis Date: 2008-05-01 Impact factor: 5.226
Authors: Andrew M Abaasa; Jim Todd; Kenneth Ekoru; Joan N Kalyango; Jonathan Levin; Emmanuel Odeke; Charles A S Karamagi Journal: BMC Health Serv Res Date: 2008-11-20 Impact factor: 2.655
Authors: Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg Journal: PLoS Med Date: 2009-10-27 Impact factor: 11.069